Life sciences company Ananda Developments PLC (AQSE: ANA) announced on Wednesday that it has contracted Southern Star Research Pty Ltd, an Australian Contract Research Organisation, to conduct a Phase 1 clinical trial for its lead investigative asset, MRX1.
This study will assess the pharmacokinetic (PK) profile, tolerability and safety of MRX1 in 20 healthy volunteers.
To be conducted in Australia, the trial will generate crucial data for future regulatory applications with agencies such as the MHRA and FDA.
The decision to conduct the study in Australia provides financial benefits, including a 43.5% R&D tax incentive.
This trial is a key step in advancing MRX1, an oral drug candidate aimed at treating complex inflammatory pain conditions, with Phase 2 trials planned for chemotherapy-induced peripheral neuropathy and endometriosis.
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
NeuroSense Therapeutics pursues early commercialisation of ALS treatment in Canada
Ananda Developments PLC signs contract for Phase 1 PK study on MRX1
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps